[Possibility of utilizing lymphatic leukemia L1210 as a first screening model in the primary selection of new antitumor antibiotics].
D000284:Administration, Oral; D000617:Aminoglycosides / Q000627:therapeutic use; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D003609:Dactinomycin / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D006824:Hybridization, Genetic; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D007939:Leukemia L1210 / Q000188:drug therapy*; D008727:Methotrexate / Q000627:therapeutic use; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D009279:Naphthacenes / Q000627:therapeutic use; D009368:Neoplasm Transplantation; D009848:Olivomycins / Q000627:therapeutic use; D013308:Streptonigrin / Q000627:therapeutic use; D013997:Time Factors
D000617:Aminoglycosides; D000903:Antibiotics, Antineoplastic; D009279:Naphthacenes; D003609:Dactinomycin; D013308:Streptonigrin; D009848:Olivomycins; D008727:Methotrexate; D003630:Daunorubicin
K voprosu o vozmozhnosti ispol'zovaniia limfaticheskogo leĭkoza L1210 v kachestve pervoĭ otseivaiushcheĭ modeli pri pervichnom otbore novykh protivoopukholevykh antibiotikov